AbbVie Pays $10.1 Billion for ImmunoGen to Expand Its Cancer Drug Portfolio
AbbVie is buying rival biotech firm ImmunoGen for $10.1 billion, giving it access to ImmunoGen's flagship ovarian cancer treatment.
( 17
min )